Scotland: £60m for genomic medicine
Enlarge image


Scotland: £60m for genomic medicine

29.08.2012 - A pioneering genetics research centre at the University of Edinburgh receives £60m (€75,6m) funding from the Medical Research Council (MRC).

The university has also received a £3.5m (€4,4m) award from the Wellcome Trust and Wolfson Foundation to help fund the building of a new systems medicine centre. The MRC funding will be used to fund research at Edinburgh's MRC Human Genetics Unit and the MRC Institute of Genetics and Medicine (IGMM) into a range of conditions, such as schizophrenia, cystic fibrosis, and genetic eye disorders, and to develop and test new therapies. IGMM is a partnership between the MRC, the University of Edinburgh's Centre for Molecular Medicine, and Cancer Research UK.

“This funding will help us to turn the potential of the genetic revolution into reality” said Institute director Nick Hastie in a video. He explained that most of the money would continue to fund ongoing programmes in the Human Genetics Unit, but that “ten to twenty percent, combined with money from the University of Edinburgh, will allow us to do exciting new science”. This would include recruiting top researchers, purchasing new equipment, developing a brand new PhD programme and helping the centre to integrate its research with the NHS. Professor Hastie said that the ‘big aim’ was to bring the results of research into clinical practice to aid the diagnosis and treatment of disease.

The £3.5m in funding from the Wellcome Trust and the Wolfson Foundation, awarded under the Wellcome-Wolfson Capital Awards programme, will support a new systems medicine building with the construction set to start in 2013 at Edinburgh's Western General Hospital. The five-story systems medicine building will total 2,700 meters squared, and will "create a physical and intellectual bridge between centres that make up the IGMM. In addition to research spaces, the facility will include spaces for computational biology, a seminar room, offices, and an "open design" to encourage research collaborations, according to IGMM. The remainder of the estimated £10.2m for the systems medicine facility will be provided by the University of Edinburgh and the MRC.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD40.9%
  • CELLECTIS (F)30.70 EUR32.3%


  • EPIGENOMICS (D)1.87 EUR-58.5%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5342.9%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR254.3%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 26.11.2015